Clinical trial · Interventional
Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms.
Pilot Study for the Development of a Non-invasive Diagnostic Score to Differentiate Between Essential Thrombocythemia, Premyelofibrosis and Myelofibrosis
NCT03869476CI-TRIAL-00084178BioScoreSMPcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective study for the development of a non-invasive score for differentiating prefibrotic myelofibrosis from essential thrombocytosis and overt myelofibrosis.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Essential Thrombocythemia | Essential Thrombocythemia | ONTOLOGY_EXACT | 0.98 |
| Myeloproliferative Disorder | Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Primary Myelofibrosis, Fibrotic Stage | Overt Primary Myelofibrosis | ALIAS | 0.90 |
| Primary Myelofibrosis, Prefibrotic Stage | Prefibrotic Primary Myelofibrosis | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-invasive diagnosis score | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- BioscoreSMP cohort
- interventionNames
- Diagnostic Test: Non-invasive diagnosis score
Primary outcomes (1)
- measure
- WHO 2016 criteria for prefibrotic myelofibrosis, essential thrombocytosis and overt myelofibrosis diagnosis
- timeFrame
- At the time of diagnosis : disease classification
- description
- Assessment of the non-invasive diagnostic score against the WHO diagnosis
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * Adult (18 years of age or older) with the diagnosis of essential thrombocytosis, prefibrotic myelofibrosis or overt myelofibrosis according to WHO 2016 criteria; * Patient who has not received specific treatment for neoplasms; * Patient who has signed the consent to participate in the study; * Patient who has consented to be included in the "Malignant Haemopathies" collection at the University Hospital of Angers or Brest and for whom the samples necessary for the study are available in the biocollection. Exclusion Criteria: * Patient with another hematologic neoplasm or progressive cancer at the time of diagnosis; * Patient with a diagnosis of secondary myelofibrosis; * Pregnant or breastfeeding woman; * Person prived of liberty by judicial or administrative decision; * Person subject to a legal protection measure;
References
Publications (0)
Data not yet available
No reference posted for this study.